scholarly journals Increased Micronuclei Frequency in Oral and Lingual Epithelium of Treated Diabetes Mellitus Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Jesús Emilo Quintero Ojeda ◽  
Maribel Aguilar-Medina ◽  
Vicente Olimón-Andalón ◽  
Rosa Alicia García Jau ◽  
Alfredo Ayala Ham ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Epithelial Cells ◽  
Onset Time ◽  
Healthy Controls ◽  
Lingual Epithelium ◽  
Nuclear Abnormalities ◽  
Dental Visits ◽  
Chronic Hyperglycemia

Diabetes mellitus (DM) is a metabolic disease characterized by persistent high levels of glucose in plasma. Chronic hyperglycemia is thought to increase oxidative stress and the formation of free radicals that in turn damage cells. Thus, we decided to determine the frequency of nuclear abnormalities in epithelial cells from cheek and tongue mucosa of DM patients with type 1 (DM1, treated only with insulin) and type 2 (DM2, treated with metformin) using the buccal micronucleus cytome (BMCyt) assay. Micronuclei frequency in cheek epithelial cells was higher in both DM1 (0.75 ± 0.31, P<0.001) and DM2 (0.52 ± 0.27, P<0.001) patients, as compared to healthy controls (0.07  ±  0.06). Similarly, micronuclei frequency in tongue epithelium was increased in DM1 (0.81  ±  0.22, P<0.001) and DM2 (0.41  ±  0.21, P<0.001) groups, in comparison to controls (0.06  ±  0.05). Besides, we found a positive correlation between micronuclei frequency and the onset time of DM2 in both cheek (ρ = 0.69, P<0.001) and tongue epithelial cells (ρ = 0.71, P<0.001), but not with onset time of DM1 or age of the patients. Considering all this, we pose that BMCyt could serve as a fast and easily accessible test to assess genotoxic damage during dental visits of DM patients, helping to monitor their disease.

Is there an HbA1c Threshold for Symptoms of Chronic Hyperglycemia?

2021 ◽  
Author(s):  
Nicolle Müller ◽  
Thomas Lehmann ◽  
Ulrich Alfons Müller ◽  
Christof Kloos
Keyword(s):  
Diabetes Mellitus ◽  
Safety Margin ◽  
Well Being ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Chronic Hyperglycemia ◽  
Patients With Diabetes ◽  
The Mean

Abstract Aims of the study The minimum therapeutic goal regarding metabolic control for people with diabetes mellitus is the “absence of symptoms of hyperglycemia.” However, it is uncertain whether a level of HbA1c can be defined that guarantees the absence of these symptoms. The aim was to define an HbA1c threshold above which most patients show hyperglycemic symptoms. Methods In a multicenter cross-sectional study, 137 patients with type 1 and 285 with type 2 diabetes were asked about their symptoms during periods of hyperglycemia with a standardized questionnaire. Seventeen symptoms of hyperglycemia were summarized to the total hyperglycemia symptom score (THSS; min. 0; max. 68). The answers could be given according to the frequency and intensity in the last 4 – 6 weeks. Results The HbA1c threshold above which most patients showed hyperglycemic symptoms was 10.05% for patients with diabetes type 1 and 8.9%. for patients with type 2. Most confidence was reached on the symptoms of frequent urination” and “tiredness.” The mean THSS was 19.4 (±9.0) and showed a positive correlation with age (r=0.167; p<0.001) and HbA1c (r=0.254; p<0.001). Conclusions We identified an HbA1c threshold above which most patients show symptoms of hyperglycemia. In the treatment of people with diabetes mellitus, a safety margin to this threshold should be maintained to preserve well-being and avoid distress. However, since hyperglycemia symptoms are subject to many influencing factors, an adjustment of the therapy—both intensification and de-intensification—should always be carried out in combination with the requested hyperglycemia symptoms and HbA1c value.

scholarly journals DOENÇA PERI-IMPLANTAR EM PACIENTE COM DIABETES MELLITUS TIPO 2: RELATO DE CASO

2016 ◽  
Vol 7 (4) ◽  
Author(s):  
Jamille Freitas De Andrade Neri ◽  
Roberta Santos Tunes ◽  
Maurício Andrade Barreto ◽  
Morbeck Dos Santos Leal Jr. ◽  
Caroline Argolo Brito de Oliveira ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Dental Implants ◽  
Metabolic Disorders ◽  
Disease Process ◽  
Chronic Hyperglycemia ◽  
Type 2 Dm ◽  
Mandibular Region ◽  
Stress Oxidative

Treatment with osseointegrated dental implants has been widely used throughout the world. However, it reveals biological complications and has been associated with dental implants’ lost. These changes can be classified into peri-implant mucositis and peri-implantitis. There are multiple factors associated with peri-implant changes, among them, diabetes mellitus (DM). DM is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in the secretion or action of insulin and may be DM type 1 or type 2 DM. It presents influence on peri-implant health since it is responsible for increased inflammation, stress oxidative and cell apoptosis with consequent delay in healing. The peri-implantitis is most responsible for the loss of dental implants, so we know the DM interface in the disease process is key to creating protocols for prevention, treatment and maintenance of peri-implant health. The objective of this study is to report the case of a patient with obesity and type 2 diabetes mellitus, rehabilitated with 4 dental implants in posterior and bilateral mandibular region in the years 2008/2009 that after five years, presented peri-implantitis in rehabilitated units with considerable bone loss.

scholarly journals Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Wanwan Luo ◽  
Lingmin Zhang ◽  
Lingling Sheng ◽  
Zhencheng Zhang ◽  
Zaixing Yang
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Patients With Diabetes ◽  
Severe Degree ◽  
The Relationship

Abstract Background: Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.Methods: Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case-control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese.Results: Twenty-five studies involving 2498 DM patients and 1424 healthy controls were included. Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD=1.62, 95%CI, 1.08 to 2.25, P=0.000; GDM: SMD=2.85, 95%CI, 1.01 to 4.70, P=0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD=1.58, 95%CI, 0.59 to 2.56, P=0.002; microalbuminuria: SMD=2.57, 95%CI, 0.92 to 4.22, P=0.002; macroalbuminuria: SMD=2.69, 95%CI, 1.40 to 3.98, P=0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD=1.49, 95%CI, 0.28 to 2.71, P=0.016; macroalbuminuria vs microalbuminuria: SMD=0.93, 95%CI, 0.34 to 1.52, P=0.002).Conclusions: DM patients have higher levels of YKL-40 compared with healthy controls. Additionally, levels of YKL-40 are significantly higher in DM patients with different degree of albuminuria than in the healthy controls and the levels of YKL-40 are positively related with the severe degree of albuminuria. Therefore, our current meta-analysis suggests that their sera should be detected for YKL-40, if DM, especially DN, is suspected in patients.

scholarly journals Increased Levels of YKL-40 in Patients With Diabetes Mellitus: A Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Wanwan Luo ◽  
Lingmin Zhang ◽  
Lingling Sheng ◽  
Zhencheng Zhang ◽  
Zaixing Yang
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Patients With Diabetes ◽  
Severe Degree ◽  
The Relationship

Abstract Background: Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.Methods: Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case-control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese.Results: Twenty-five studies involving 2498 DM patients and 1424 healthy controls were included. Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD=1.62, 95%CI, 1.08 to 2.25, P=0.000; GDM: SMD=2.85, 95%CI, 1.01 to 4.70, P=0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD=1.58, 95%CI, 0.59 to 2.56, P=0.002; microalbuminuria: SMD=2.57, 95%CI, 0.92 to 4.22, P=0.002; macroalbuminuria: SMD=2.69, 95%CI, 1.40 to 3.98, P=0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD=1.49, 95%CI, 0.28 to 2.71, P=0.016; macroalbuminuria vs microalbuminuria: SMD=0.93, 95%CI, 0.34 to 1.52, P=0.002).Conclusions: DM patients have higher levels of YKL-40 compared with healthy controls. Additionally, levels of YKL-40 are significantly higher in DM patients with different degree of albuminuria than in the healthy controls and the levels of YKL-40 are positively related with the severe degree of albuminuria.

scholarly journals Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Wanwan Luo ◽  
Lingmin Zhang ◽  
Lingling Sheng ◽  
Zhencheng Zhang ◽  
Zaixing Yang
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Patients With Diabetes ◽  
Severe Degree ◽  
The Relationship

Abstract Background Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN. Methods Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case–control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese. Finally, twenty-five studies were included in this meta-analysis. Results Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD = 1.62, 95% CI 1.08 to 2.25, P = 0.000; GDM: SMD = 2.85, 95% CI 1.01 to 4.70, P = 0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD = 1.58, 95% CI 0.59 to 2.56, P = 0.002; microalbuminuria: SMD = 2.57, 95% CI 0.92 to 4.22, P = 0.002; macroalbuminuria: SMD = 2.69, 95% CI 1.40 to 3.98, P = 0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD = 1.49, 95% CI 0.28 to 2.71, P = 0.016; macroalbuminuria vs microalbuminuria: SMD = 0.93, 95% CI 0.34 to 1.52, P = 0.002). Conclusions Our current meta-analysis demonstrates that serum level of YKL-40 is increased in DM and positively associated with the severe degree of albuminuria. Therefore, we suggest that YKL-40 could be considered to be detected, along with other inflammatory markers, if DM, especially DN, is suspected.

scholarly journals New Frontier in the Treatment of Diabetes

2019 ◽  
Vol 9 (5-s) ◽  
pp. 178-187
Author(s):  
Abhishek Jayesh Bhatt ◽  
Arya Sudhanshu Vyas ◽  
Devarshi Priyesh Shah
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Diseases ◽  
Diabetes Type 2 ◽  
Secondary Diabetes ◽  
Novel Technologies ◽  
Chronic Hyperglycemia ◽  
Treatment Of Diabetes

Diabetes mellitus is a group of metabolic diseases recognized by chronic hyperglycemia resulting from defects in secretion in insulin, insulin action or both. There are different types of diabetes like Type 1, type 2, gestational diabetes, secondary diabetes, wolfram syndrome and autoimmune polyglandular syndrome. Type 1 and type 2 diabetes are most common type of diabetes. Polydipsia, polyuria, polyphagia, weight loss slow wound healing, etc. are common symptoms of Diabetes. Diabetes can be genetic; autoimmune, medical related or even diet related. In this article causes and treatment of diabetes is discussed in detail. It includes glimpse of novel technologies like patches, pump and pens, etc. It also includes momentary of other treatment like oral and Injectable hypoglycemic drug and surgical treatments. A glance of latest innovation for measuring glucose level in body with help of sweat, breath and saliva are explained. Keywords: Diabetes; Type 2 Diabetes Mellitus (TY2DM), Polydipsia, polyuria, polyphagia, clicksoft microinjection, insulin pen, v-go

scholarly journals Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Wanwan Luo ◽  
Lingmin Zhang ◽  
Lingling Sheng ◽  
Zhencheng Zhang ◽  
Zaixing Yang
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Meta Analysis ◽  
Healthy Controls ◽  
Patients With Diabetes ◽  
Severe Degree ◽  
The Relationship

Abstract Background: Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.Methods: Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case-control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese. Finally, twenty-five studies were included in this meta-analysis.Results: Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD=1.62, 95%CI, 1.08 to 2.25, P=0.000; GDM: SMD=2.85, 95%CI, 1.01 to 4.70, P=0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD=1.58, 95%CI, 0.59 to 2.56, P=0.002; microalbuminuria: SMD=2.57, 95%CI, 0.92 to 4.22, P=0.002; macroalbuminuria: SMD=2.69, 95%CI, 1.40 to 3.98, P=0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD=1.49, 95%CI, 0.28 to 2.71, P=0.016; macroalbuminuria vs microalbuminuria: SMD=0.93, 95%CI, 0.34 to 1.52, P=0.002).Conclusions: Our current meta-analysis demonstrates that serum level of YKL-40 is increased in DM and positively associated with the severe degree of albuminuria. Therefore, we suggest that YKL-40 could be considered to be detected, along with other inflammatory markers, if DM, especially DN, is suspected.

Lack of Evidence Linking Infant Feeding Regimen and Type 1 or Type 2 Diabetes Mellitus

PEDIATRICS ◽  
2016 ◽  
Vol 137 (Supplement 3) ◽  
pp. 237A-237A
Author(s):  
Robin S. Feldman ◽  
Michael Falk ◽  
Kathy A. Grako ◽  
Dawn A. Groenke ◽  
Allison Cooke ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Infant Feeding ◽  
Feeding Regimen
Sign in / Sign up

Export Citation Format

Share Document